Claims Study Looks at Outcomes Prior to a Therapeutic Switch for ATTR-CM
Key Highlights
- The study examined claims recorded before acoramidis initiation; it did not assess outcomes after the switch.
- In the 12 months before switching, 34.1% of patients had a cardiovascular-related hospitalization and 31.8% had a cardiovascular-related emergency department visit that did not lead to hospitalization.
- During the final 6 months before switching, 31.8% had diuretic intensification and 49.2% had at least one event in the combined measure of hospitalization, emergency department visit, or diuretic intensification.
Nearly half of a cohort of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who switched from tafamidis to acoramidis had a cardiovascular-related event or diuretic intensification in the 6 months before the switch. These findings were presented as part of the Heart Failure Society of American 2026 Annual Scientific Meeting.
Researchers used the Komodo Healthcare Map to identify adults with at least one acoramidis claim from December 2024 through August 2025 and at least one tafamidis claim during the preceding 12 months. They measured cardiovascular-related hospitalizations, cardiovascular-related emergency department visits that did not lead to hospitalization, and diuretic intensification before acoramidis initiation.
Diuretic intensification included a new or increased oral loop diuretic-equivalent dose, parenteral loop diuretic use in an emergency department or outpatient setting, or addition of a thiazide diuretic. For this measure, the researchers used the first 6 months of the year before switching as baseline and assessed new or intensified use in the final 6 months.
Study Findings
The study identified 132 patients who switched from tafamidis to acoramidis. Their mean age was 78.3 years, 75.8% were male, and 94.7% had more than one tafamidis claim before switching. Loop diuretic use was recorded in 76.5%.
Cardiovascular-related hospitalization occurred in 14.4%, 23.5%, and 34.1% of patients during the 3, 6, and 12 months before the switch, respectively. The corresponding proportions for cardiovascular-related emergency department visits were 11.4%, 18.9%, and 31.8%. Across those periods, 19.7%, 31.8%, and 47.7% had either type of cardiovascular-related encounter.
During the final 6 months before acoramidis initiation, 31.8% had diuretic intensification. Overall, 49.2% had at least one cardiovascular-related hospitalization, cardiovascular-related emergency department visit, or diuretic intensification during that period.
Clinical Implications
According to the authors, these findings document a substantial burden of markers of clinical worsening before patients switched therapies. They called for research into why patients switch and what happens after acoramidis initiation. The abstract does not include a limitations section.
Expert Commentary
“Future research should evaluate drivers of switching therapy and outcomes after transitioning to acoramidis,” the researchers concluded.
Wright R, Stern LK, Grodin JL, et al. Real-world burden of transthyretin amyloid cardiomyopathy disease and outcomes in patients on tafamidis before switching to acoramidis. HFSA ePoster Library. October 10, 2026. Poster 4235111.